Tag: Algernon Pharmaceuticals - Page 2

Psilocybin Alpha is becoming Psychedelic Alpha - Please bear with us.

Read more about the article Algernon Pharmaceuticals Submits U.S. FDA Pre-IND Meeting Request for Psychedelic Drug DMT Clinical Research Program for Stroke

Algernon Pharmaceuticals Submits U.S. FDA Pre-IND Meeting Request for Psychedelic Drug DMT Clinical Research Program for Stroke

Post published:March 17, 2021
Post category:Press Release

Algernon Pharmaceuticals to Conduct Phase 1 DMT Stroke Program Study with Hammersmith Medicines Research (UK)

Post published:March 1, 2021
Post category:Press Release

Algernon Pharmaceuticals Awards DMT Manufacturing Contract to Dalton Pharma for Stroke Program

Post published:February 19, 2021
Post category:Press Release

Algernon Pharmaceuticals Signs Agreement with Charles River Laboratories for DMT Preclinical Studies

Post published:February 8, 2021
Post category:Press Release

Read more about the article Algernon Pharmaceuticals Launches Stroke Treatment Clinical Research Program with Psychedelic Drug DMT “The Spirit Molecule”

Algernon Pharmaceuticals Launches Stroke Treatment Clinical Research Program with Psychedelic Drug DMT “The Spirit Molecule”

Post published:February 1, 2021
Post category:Press Release

End of content

No more pages to load

Newer Posts

Psychedelic Alpha

Psychedelic Alpha is an independent newsletter and community that strives to empower a diverse constellation of individuals and organisations with the knowledge, network and nuance to make an impact within the field of psychedelic medicine and beyond

Quick Links

Insights and interviews delivered to your inbox. No spam, just valuable information.

Weekly Bulletin

Your weekly recap of news and analysis from the psychedelic sector.

Research Review

A monthly review of the most important psychedelics research.

News & Interviews

The latest news from across the psychedelics space.

Psychedelics Patent Trackers

We track the latest patents and filings related to psilocybin, MDMA and DMT.

Psychedelic Legalization & Decriminalization Tracker

Mapping psychedelic drug policy reform across the United States

Psychedelics Drug Development Tracker

From drug discovery to regulatory approval, we map drug development in psychedelics.

Stocks & Companies Directory

A directory of all the major psychedelics stocks, companies and ETFs.

Sector Landscape Map

Explore the Psychedelic Sector Landscape visually using our new tool.

Stock Watchlist

A one-stop overview of psychedelics stocks financial performance.

Algernon Pharmaceuticals Submits U.S. FDA Pre-IND Meeting Request for Psychedelic Drug DMT Clinical Research Program for Stroke

Algernon Pharmaceuticals to Conduct Phase 1 DMT Stroke Program Study with Hammersmith Medicines Research (UK)

Algernon Pharmaceuticals Awards DMT Manufacturing Contract to Dalton Pharma for Stroke Program

Algernon Pharmaceuticals Signs Agreement with Charles River Laboratories for DMT Preclinical Studies

Algernon Pharmaceuticals Launches Stroke Treatment Clinical Research Program with Psychedelic Drug DMT “The Spirit Molecule”

Psychedelic Alpha

Quick Links

Newsletter

Join Our Newsletter

Psychedelic sector insights, interviews and analysis delivered to your inbox.

No thanks, continue to site.